Literature DB >> 17089015

Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro.

Raffaella Spinazzi1, Giovanna Albertin, Beatrice Nico, Diego Guidolin, Rosa Di Liddo, Gian Paolo Rossi, Domenico Ribatti, Gastone G Nussdorfer.   

Abstract

Urotensin-II (UII), along its receptor UT-R, is widely expressed in the cardiovascular system, where it exerts regulatory actions under both physiological and pathological conditions. Real-time PCR and immunocytochemistry demonstrated the expression of UII and UT-R as mRNA and protein in rat neuromicrovascular endothelial cells (NECs). UII did not affect the proliferation rate of cultured NECs, but exerted a strong angiogenic action in both an in vitro assay on Matrigel and an in vivo assay on chorioallantoic membrane. The angiogenic effect of UII was similar to that of FGF-2, and was abolished by the UT-R antagonist Palosuran. Collectively, our findings allow us to include UII in the group of cytokines (e.g. endothelin-1 and adrenomedullin), which are expressed in endothelial cells and exert a pro-angiogenic effect acting in an autocrine-paracrine manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089015

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  11 in total

1.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

2.  The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.

Authors:  Onder Yumrutas; Serdar Oztuzcu; Hakan Büyükhatipoglu; Ibrahim Bozgeyik; Esra Bozgeyik; Yusuf Ziya Igci; Haydar Bagis; M Ozgur Cevik; M Emin Kalender; Zeynep Eslik; Ahmet Arslan
Journal:  Tumour Biol       Date:  2015-01-22

3.  Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Authors:  D J Behm; J J McAtee; J W Dodson; M J Neeb; H E Fries; C A Evans; R R Hernandez; K D Hoffman; S M Harrison; J M Lai; C Wu; N V Aiyar; E H Ohlstein; S A Douglas
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

4.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

5.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

6.  Seasonal changes in patterns of gene expression in avian song control brain regions.

Authors:  Christopher K Thompson; John Meitzen; Kirstin Replogle; Jenny Drnevich; Karin L Lent; Anne Marie Wissman; Federico M Farin; Theo K Bammler; Richard P Beyer; David F Clayton; David J Perkel; Eliot A Brenowitz
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

Review 7.  The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Authors:  Hélène Castel; Laurence Desrues; Jane-Eileen Joubert; Marie-Christine Tonon; Laurent Prézeau; Marie Chabbert; Fabrice Morin; Pierrick Gandolfo
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

8.  DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.

Authors:  Vishakha Sharma; Naoe Harafuji; Alexandra Belayew; Yi-Wen Chen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification.

Authors:  Isabella Albanese; Stella S Daskalopoulou; Bin Yu; Zhipeng You; Jacques Genest; Alawi Alsheikh-Ali; Adel G Schwertani
Journal:  Front Pharmacol       Date:  2016-06-07       Impact factor: 5.810

10.  Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours.

Authors:  Benjamin Poret; Laurence Desrues; Marc-André Bonin; Martin Pédard; Martine Dubois; Richard Leduc; Romain Modzelewski; Pierre Decazes; Fabrice Morin; Pierre Vera; Hélène Castel; Pierre Bohn; Pierrick Gandolfo
Journal:  Biomolecules       Date:  2020-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.